All the fundraising deals in the femtech market (from Q1 2025 to Q1 2026)
Download our beautiful pitch about the femtech market
In our femtech market deck, you will find everything you need to understand the market
The femtech market kept attracting serious capital from Q1 2025 through Q1 2026, with 52 qualifying funding rounds totaling roughly $914 million across five consecutive quarters.
The funding landscape ranged from sub-million pre-seed bets on pelvic health devices to a $100 million Series D for a menopause telehealth platform, showing both breadth and concentration.
Fertility, cancer screening, and menopause care dominated investor attention, while early-stage activity in cycle health and diagnostics signals that new company formation in the femtech market remains healthy.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
In our femtech market deck, we will give you useful market maps and grids
Summary table of the funding deals in the femtech market (last 5 quarters)
We define the femtech market as technology-enabled products and services that address women's reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women (e.g., breast and gynecological cancers).
We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women's biology, care pathways, or life stages.
You can also read our detailed analysis to understand how funding activity in the femtech market has evolved over the last few years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the femtech market.
| Name | What they do | Amount | Quarter | Source(s) |
|---|---|---|---|---|
| Ataraxis AI | AI-powered clinical decision support for breast cancer precision medicine. | $20.4M | Q1 2025 | New Market Pitch |
| Arva Health | Modern fertility clinic and IVF support services for patients in India. | $1.0M | Q1 2025 | New Market Pitch |
| Uresta | Reusable intravaginal device that treats stress urinary incontinence without surgery. | $3.0M | Q1 2025 | New Market Pitch |
| Fizimed | Connected pelvic-floor training devices that guide rehabilitation exercises at home. | $4.4M | Q1 2025 | New Market Pitch |
| SimpliFed | Telehealth platform delivering lactation support and postpartum feeding guidance to new mothers. | $4.0M | Q1 2025 | New Market Pitch |
| Millie | Midwifery-led maternity clinics combining in-person care with digital tools for expectant mothers. | $12.0M | Q1 2025 | New Market Pitch |
| PinkDx | Diagnostics company focused on early detection of gynecologic cancers. | $5.0M | Q1 2025 | New Market Pitch |
| Gaia | Fertility financing and insurance platform that makes IVF treatment more affordable. | $14.0M | Q1 2025 | New Market Pitch |
| Kegg | Fertility tracking device that reads cervical fluid signals and syncs with a companion app. | $6.5M | Q1 2025 | New Market Pitch |
| Twentyeight Health | Telehealth platform providing affordable access to birth control, STI testing, and reproductive care. | $10.0M | Q1 2025 | New Market Pitch |
| Teal Health | At-home cervical cancer screening kit using self-collection and lab-grade analysis. | $10.0M | Q1 2025 | New Market Pitch |
| Delfina | AI platform that predicts maternity risk for health plans and hospital systems. | $17.0M | Q1 2025 | New Market Pitch |
| Sunfish | IVF financing platform offering outcome-based refunds if treatment is unsuccessful. | $10.0M | Q1 2025 | New Market Pitch |
| Conceivable Life Sciences | Automated IVF laboratory technology that standardizes and scales embryo culture workflows. | $50.0M | Q1 2025 | New Market Pitch |
| Allara Health | Virtual care clinic for women with PCOS, endometriosis, and other hormonal conditions. | $26.0M | Q1 2025 | New Market Pitch |
| Gesynta Pharma | Drug developer creating non-hormonal treatments for endometriosis pain. | $31.5M | Q1 2025 | New Market Pitch |
| Escala Medical | Non-surgical device designed to treat pelvic organ prolapse without invasive procedures. | $4.5M | Q2 2025 | New Market Pitch |
| Joii | Menstrual health monitoring system that uses smart pads and image analysis to track cycle patterns. | $2.6M | Q2 2025 | New Market Pitch |
| Samphire Neuroscience | Wearable neurostimulation device that reduces PMS and period pain without medication. | $5.0M | Q2 2025 | New Market Pitch |
| Magcath | Minimally invasive device addressing women's urinary incontinence. | $0.58M | Q2 2025 | New Market Pitch |
| UVISA | At-home light-therapy device for treating recurrent vaginal infections. | $0.65M | Q2 2025 | New Market Pitch |
| Hormona | At-home hormone testing kit combined with an AI-powered health insights platform for women. | $8.8M | Q2 2025 | New Market Pitch |
| Overture Life | Robotics company automating IVF laboratory procedures to improve consistency and outcomes. | $20.6M | Q2 2025 | New Market Pitch |
| ReproNovo | Biotechnology company building a drug pipeline to treat infertility and reproductive conditions. | $65.0M | Q2 2025 | New Market Pitch |
| Ovo Labs | Therapeutics company developing treatments to improve egg quality and IVF success rates. | $5.0M | Q2 2025 | New Market Pitch |
| Cofertility | Egg freezing and donation marketplace connecting individuals with family-building options. | $7.25M | Q2 2025 | New Market Pitch |
| Midi Health | Telehealth clinic specializing in menopause and perimenopause care for women. | $50.0M | Q2 2025 | New Market Pitch |
| Seven Starling | Perinatal mental health platform serving patients through fertility, pregnancy, loss, and postpartum stages. | $8.0M | Q3 2025 | New Market Pitch |
| Gameto | Reproductive biotech advancing cell-based therapies for fertility and menopause-related conditions. | $44.0M | Q3 2025 | New Market Pitch |
| Solence | Digital therapeutics app delivering personalized PCOS management and lifestyle support. | $1.7M | Q3 2025 | New Market Pitch |
| Ovasave | At-home fertility hormone testing service paired with virtual clinical support. | $1.2M | Q3 2025 | New Market Pitch |
| Plenna | Hybrid women's health clinic combining in-person visits with digital care tools. | $6.0M | Q3 2025 | New Market Pitch |
| BeSound | Ultrasound-based breast screening device designed specifically for women with dense breast tissue. | $6.8M | Q3 2025 | New Market Pitch |
| Visana Health | Virtual clinic treating endometriosis, PCOS, contraception needs, and menopause for employer health plans. | $24.0M | Q3 2025 | New Market Pitch |
| Diana Health | Hospital-partnered women's health programs delivering midwifery-inspired maternity and postpartum care. | $55.0M | Q3 2025 | New Market Pitch |
| Conceivable Life Sciences | Second round for its AI-automated IVF lab technology to launch and expand operations. | $50.0M | Q3 2025 | New Market Pitch |
| Mercy BioAnalytics | Blood-based ovarian cancer detection test enabling early diagnosis through a simple blood draw. | $59.0M | Q3 2025 | New Market Pitch |
| Pluro Fertility & IVF | Fertility clinic network and technology platform expanding IVF access across cities in India. | ~$15.0M | Q4 2025 | New Market Pitch |
| Emm | Smart menstrual cup with embedded sensors and an app layer to track cycle health data. | $9.0M | Q4 2025 | New Market Pitch |
| FamilyWell Health | Integrated behavioral health services embedded inside OB/GYN and women's health clinics. | $8.0M | Q4 2025 | New Market Pitch |
| Metri Bio | Drug discovery platform building a new therapeutic pipeline specifically for endometriosis. | $5.0M | Q4 2025 | New Market Pitch |
| Inito | At-home fertility hormone monitor that tracks four key hormones with a single test strip and smartphone. | $29.0M | Q4 2025 | New Market Pitch |
| IVFmicro | IVF culture technology improving embryo quality and yield per cycle in fertility clinics. | $4.4M | Q4 2025 | New Market Pitch |
| Micro Inno | Portable imaging device designed to improve gynecological diagnostics access in clinical settings. | $5.0M | Q4 2025 | New Market Pitch |
| Clairity | FDA-authorized AI software predicting breast cancer risk directly from standard mammogram images. | $43.0M | Q4 2025 | New Market Pitch |
| BrightHeart | AI platform for prenatal ultrasound analysis that delivers expert-level cardiac screening during routine scans. | ~$11.9M | Q1 2026 | BrightHeart |
| Feminai | At-home breast cancer screening wearable powered by AI, targeting early detection outside clinical settings. | $6.0M | Q1 2026 | New Market Pitch |
| Xella Health | Multi-omic women's health diagnostics platform using menstrual fluid and blood samples for hormonal insights. | $3.7M | Q1 2026 | New Market Pitch |
| Pinky Promise | AI-assisted digital gynecology clinic expanding reproductive care access across India. | $1.0M | Q1 2026 | New Market Pitch |
| Origin | Pelvic-floor physical therapy provider treating incontinence, pregnancy, postpartum, and sexual health conditions. | $21.0M | Q1 2026 | PR Newswire |
| Midi Health | AI-enabled women's healthcare platform scaling perimenopause, menopause, and broader life-stage care nationally. | $100.0M | Q1 2026 | Midi Health |
| 28x | Privacy-first period tracking app that processes all data on-device, with no cloud sharing. | ~$1.5M | Q1 2026 | Femtech Insider |
In our femtech market deck, we identify pain points entrepreneurs should prioritize
How has funding activity in the femtech market changed over time?
Q3 2025 was the most active quarter by total capital in the femtech market at roughly $255.7 million, driven by four deals above $44 million each (Diana Health, Mercy BioAnalytics, Conceivable Life Sciences, and Gameto) landing in the same quarter.
Q4 2025 was the quietest quarter with $118.4 million across only eight deals, and notably no single round exceeded $50 million, making it the only quarter without a mega deal in the dataset.
Compared to Q4 2025, femtech market funding in Q1 2026 rose roughly 23%, and compared to Q1 2025 one year earlier, the Q1 2026 figure was down about 35%, largely because Q1 2025 had 16 deals versus only 7 in Q1 2026.
If you strip out the top deal each quarter (Conceivable Life Sciences in Q1 2025, Midi in Q2, Mercy in Q3, Clairity in Q4, and Midi again in Q1 2026), the remaining rounds paint a more stable picture, with the femtech market averaging roughly $65 to $90 million per quarter in non-outlier capital, and deal counts staying fairly consistent between 7 and 15.
| Quarter | Number of deals | Total raised | Comment |
|---|---|---|---|
| Q1 2025 | 16 | $224.8M | Highest deal count of any quarter; capital spread broadly across fertility, diagnostics, and care delivery. |
| Q2 2025 | 11 | $170.0M | ReproNovo ($65M) and Midi Health's Series C ($50M) together accounted for 68% of quarter total. |
| Q3 2025 | 10 | $255.7M | Highest total capital; four deals above $44M each drove an unusually high mean deal size of $25.6M. |
| Q4 2025 | 8 | $118.4M | Quietest quarter overall; no single deal exceeded $50M, making it the most evenly distributed period. |
| Q1 2026 | 7 | $145.1M | Fewest deals in the period; Midi Health's $100M Series D alone represented 69% of quarterly capital. |
| All quarters | 52 | $914.0M | Roughly $914M across 52 deals over five quarters, with a mean deal size of approximately $17.6M. |
In our femtech market deck, we identify repeatable patterns you can use if you’re building in this market
Which startups in the femtech market raised the largest rounds over the last months?
These startups raised the most recently in the femtech market:
- Midi Health raised $100 million in a Series D in Q1 2026 because investors see it as the category-defining platform for AI-enabled menopause and women's midlife care, and Goodwater Capital led the round alongside Foresite Capital and Serena Ventures.
- ReproNovo raised $65 million in Q2 2025 to build out its reproductive therapeutics pipeline, targeting a largely underserved drug development space for infertility and reproductive conditions.
- Mercy BioAnalytics raised $59 million in Q3 2025 to commercialize its blood-based ovarian cancer detection test, a category where early detection can dramatically improve patient outcomes.
- Diana Health raised $55 million in Q3 2025 to scale its hospital-partnered women's health programs, which combine midwifery-led care with digital tools across health systems.
- Midi Health raised $50 million in a Series C in Q2 2025, just eight months before its Series D, to fuel rapid expansion of its menopause telehealth platform as the category began to reach mainstream scale.
- Conceivable Life Sciences raised $50 million in a Series A in both Q1 2025 and Q3 2025 to build and then expand its AI-automated IVF laboratory, making it the only company in the dataset to close two large rounds within one year.
- Gameto raised $44 million in a Series C in Q3 2025 to advance its cell-based fertility and menopause-related therapeutics programs toward clinical milestones.
- Clairity raised $43 million in Q4 2025 to launch its FDA-authorized AI breast cancer risk prediction platform into clinical and health system workflows.
- Gesynta Pharma raised $31.5 million in Q1 2025 to advance its non-hormonal endometriosis drug pipeline, addressing a condition that affects roughly 190 million women worldwide with limited treatment options.
- Inito raised $29 million in a Series B in Q4 2025 to scale its at-home fertility hormone testing platform, which lets women track four key hormones with a single strip and their smartphone.
And, yes, we do cover most of them in our beautiful pitch about the femtech market.
You may also want to check our ranking of the most funded startups in the femtech market as well as our list of the most valued startups.
In our femtech market deck, we answer all the common questions from investors and entrepreneurs
Is the femtech market shifting toward smaller or bigger deals?
Across all five quarters, the average femtech funding round came in at roughly $17.6 million, but that figure is pulled up by a handful of mega deals and masks a large number of rounds below $10 million.
The mean deal size in the femtech market moved from $14.1 million in Q1 2025 up to $25.6 million in Q3 2025, then pulled back to $14.8 million in Q4 2025, and recovered to $20.7 million in Q1 2026; this variation is almost entirely driven by whether one or two very large rounds landed in a given quarter, not by any structural shift in early-stage funding behavior.
If you remove the single largest deal from each quarter, the remaining rounds in the femtech market are remarkably consistent, clustering between roughly $5 million and $15 million, which suggests that the underlying deal-size trend is actually quite stable at the middle market, and the volatility is almost entirely a large-round effect.
| Quarter | Number of deals | Average deal size | Deals below $2M | Deals above $50M |
|---|---|---|---|---|
| Q1 2025 | 16 | $14.1M | 1 | 0 |
| Q2 2025 | 11 | $15.5M | 2 | 1 |
| Q3 2025 | 10 | $25.6M | 2 | 2 |
| Q4 2025 | 8 | $14.8M | 0 | 0 |
| Q1 2026 | 7 | $20.7M | 2 | 1 |
| All quarters | 52 | $17.6M | 7 | 4 |
In our femtech market deck, we help you understand how the market is structured
How concentrated was funding activity in the femtech market?
Funding concentration in the femtech market has actually been increasing over the five quarters tracked: in Q1 2025, the top deal represented 22% of quarterly capital, while in Q1 2026 a single deal (Midi Health) absorbed nearly 69% of the quarter's total. This trend means the femtech market is becoming more, not less, winner-take-most at the top.
The top three deals per quarter consistently captured between 48% and 92% of quarterly femtech funding across the period, which means that a few category leaders are pulling away while the rest of the market raises substantially smaller checks.
| Quarter | Number of deals | % by top 1 | % by top 3 | % by top 10 |
|---|---|---|---|---|
| Q1 2025 | 16 | 22.2% | 47.8% | 89.4% |
| Q2 2025 | 11 | 38.2% | 79.8% | 99.7% |
| Q3 2025 | 10 | 23.1% | 64.1% | 100.0% |
| Q4 2025 | 8 | 36.3% | 73.5% | 100.0% |
| Q1 2026 | 7 | 68.9% | 91.6% | 100.0% |
| All quarters | 52 | ~34% | ~71% | ~98% |
In our femtech market deck, we have designed useful charts to give you full market clarity
Which categories in the femtech market received the most funding?
Fertility and IVF captured roughly $172.7 million across 10 deals, the most of any category in the femtech market, because investors continue to see it as the clearest pathway to large, repeatable revenue: every sub-category from clinic networks and lab automation to financing and hormone testing attracted capital, confirming that fertility is a full-stack investment theme rather than a single product bet.
Oncology and screening raised approximately $150.2 million across eight deals, reflecting a broader shift in femtech toward regulated, clinically legible products, with breast, cervical, ovarian, and gynecological cancer detection all attracting separate investments and several rounds landing well above $20 million.
Menopause and midlife care reached $150 million across just two deals, both belonging to Midi Health, which tells you that when a femtech category matures, the capital concentration becomes extreme and a single platform can absorb most available institutional funding.
| Category name | Number of deals | Total raised | Startups and amounts |
|---|---|---|---|
| Fertility & IVF | 10 | $172.7M | Arva Health ($1.0M), Gaia ($14.0M), Kegg ($6.5M), Sunfish ($10.0M), Conceivable Life Sciences ($50.0M, Q1 2025), Overture Life ($20.6M), Ovasave ($1.2M), Conceivable Life Sciences ($50.0M, Q3 2025), Pluro Fertility & IVF (~$15.0M), IVFmicro ($4.4M) |
| Oncology & screening | 8 | $150.2M | Ataraxis AI ($20.4M), PinkDx ($5.0M), Teal Health ($10.0M), BeSound ($6.8M), Mercy BioAnalytics ($59.0M), Clairity ($43.0M), Feminai ($6.0M) |
| Menopause & midlife care | 2 | $150.0M | Midi Health ($50.0M, Q2 2025), Midi Health ($100.0M, Q1 2026) |
In our femtech market deck, we cover the latest tech updates shaping the market
Who are the biggest investors in the femtech market?
.406 Ventures backed both Diana Health and FamilyWell Health, making it the most active disclosed repeat investor in the femtech market during this period, with a clear focus on women's care delivery models embedded within or adjacent to health systems.
Mother Ventures invested in both Sunfish and Millie, concentrating on the fertility financing and maternity care segments of the femtech market, and stands out as one of the few specialist funds with multiple disclosed deals in the dataset.
Goodwater Capital led Midi Health's $100 million Series D in Q1 2026, making it the lead investor in the single largest femtech funding round tracked over the five-quarter period.
Precursor Ventures led the pre-seed round in Xella Health in Q1 2026, signaling early conviction in multi-omic menstrual diagnostics as a new frontier in the femtech market.
SJF Ventures led Origin's $21 million Series B in Q1 2026, backing the pelvic-floor physical therapy platform as it scales access to women's musculoskeletal care across the country.
Odyssée Venture and GO Capital co-led BrightHeart's Series A in Q1 2026, funding the AI prenatal ultrasound platform's expansion into the U.S. and European markets.
Rethink Impact participated in Seven Starling's $8 million round in Q3 2025, investing in the perinatal mental health platform as it expanded its state footprint and deepened OB/GYN integrations.
New Markets Venture Partners backed FamilyWell Health in Q4 2025, supporting the integration of behavioral health services inside women's health clinic workflows.
Bessemer Venture Partners participated in Pluro Fertility and IVF's Series A in Q4 2025, one of the few top-tier generalist firms with a disclosed femtech deal in the dataset.
In our femtech market deck, we track adoption trends and shifts in consumer behavior
Related blog posts
- All the funding deals announced in the femtech market
- Which companies have raised the most funding in the femtech market?
